Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amisulpride
Drug ID BADD_D00117
Description Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression.[A6755] Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation.[L32764] Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea and vomiting in adults, either as monotherapy or in combination with another antiemetic agent of a different drug class.[L32759] It is marketed under the brand name Barhemsys.
Indications and Usage Investigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression.
Marketing Status Not Available
ATC Code N05AL05
DrugBank ID DB06288
KEGG ID D07310
MeSH ID D000077582
PubChem ID 2159
TTD Drug ID D03ELL
NDC Product Code 71390-125; 51604-1156
Synonyms Amisulpride | 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide | DAN 2163 | DAN-2163 | Solian | Sultopride | N-(Ethyl-1-pyrrolidinyl- 2-methyl)methoxy-2-ethylsulfonyl-5-benzamide | LIN 1418 | LIN-1418 | Barnetil | Sultopride Hydrochloride
Chemical Information
Molecular Formula C17H27N3O4S
CAS Registry Number 71675-85-9
SMILES CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypokinesia17.01.02.009--Not Available
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Leukopenia01.02.02.001--Not Available
Menstrual disorder21.01.01.004--Not Available
Muscle rigidity17.05.02.005; 15.05.04.001--Not Available
Muscle spasms15.05.03.004--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.004--Not Available
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pregnancy18.08.02.004--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Sudden death08.04.01.003; 02.03.04.013--
Suicide attempt19.12.01.004--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages